Retinoblastoma

1. Villegas VM, Hess DJ, Wildner A, et al. Retinoblastoma. Curr Opin Ophthalmol. 2013 Nov;24(6):581-8[Abstract]

2. National Organization for Rare Disorders. Rare diseases database. Retinoblastoma. 2017 [internet publication].[Full Text]

3. Schefler AC, Abramson DH. Retinoblastoma: what is new in 2007-2008. Curr Opin Ophthalmol. 2008 Nov;19(6):526-34.[Abstract]

4. Akdeniz Odemis D, Kebudi R, Bayramova J, et al. RB1 gene mutations and genetic spectrum in retinoblastoma cases. Medicine (Baltimore). 2023 Sep 8;102(36):e35068.[Abstract][Full Text]

5. Chai P, Luo Y, Yu J, et al. Clinical characteristics and germline mutation spectrum of RB1 in Chinese patients with retinoblastoma: a dual-center study of 145 patients. Exp Eye Res. 2021 Apr;205:108456.[Abstract]

6. Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin N Am. 2005;18:41-53.[Abstract]

7. Abramson DH, Schefler AC. Update on retinoblastoma. Retina. 2004 Dec;24(6):828-48.[Abstract]

8. Cassoux N, Lumbroso L, Levy-Gabriel C, et al. Retinoblastoma: update on current management. Asia Pac J Ophthalmol (Phila). 2017 May-Jun;6(3):290-5.[Abstract]

9. Global Retinoblastoma Study Group, Fabian ID, Abdallah E, et al. Global retinoblastoma presentation and analysis by national income level. JAMA Oncol. 2020 May 1;6(5):685-95.[Abstract][Full Text]

10. Ghose N, Agarwal P, Palkonda VAR, et al. Retinoblastoma associated with total exudative retinal detachment: treatment and outcomes. Retina. 2023 May 1;43(5):808-14.[Abstract]

11. Ortiz MV, Dunkel IJ. Retinoblastoma. J Child Neurol. 2016 Feb;31(2):227-36.[Abstract]

12. Walinjkar J, Krishnakumar S, Gopal L, et al. Retinoblastoma presenting with orbital cellulitis. J AAPOS. 2013 Jun;17(3):282-6.[Abstract]

13. O'Brien JM. Retinoblastoma: clinical presentation and the role of neuroimaging. AJNR Am J Neuroradiol. 2001 Mar;22(3):426-8.[Abstract][Full Text]

14. Kamihara J, Bourdeaut F, Foulkes WD, et al. Retinoblastoma and neuroblastoma predisposition and surveillance. Clin Cancer Res. 2017 Jul 1;23(13):e98-106.[Abstract][Full Text]

15. Ballarati L, Elena Rossi E, Bonati MT, et al. 13q deletion and central nervous system anomalies: further insights from karyotype - phenotype analyses of 14 patients. J Med Genet. 2007;44:e60.[Abstract]

16. Tamboli A, Podgor MJ, Horm JW. The incidence of retinoblastoma in the United States: 1974 through 1985. Arch Ophthalmol. 1990 Jan;108(1):128-32.[Abstract]

17. Aerts I, Lumbroso-Le Rouic L, Gauthier-Villars M, et al. Retinoblastoma. Orphanet J Rare Dis. 2006 Aug 25;1:31.[Abstract][Full Text]

18. Fernandes AG, Pollock BD, Rabito FA. Retinoblastoma in the United States: a 40-year incidence and survival analysis. J Pediatr Ophthalmol Strabismus. 2018 May 1;55(3):182-8.[Abstract]

19. Wong JR, Tucker MA, Kleinerman RA, et al. Retinoblastoma incidence patterns in the US Surveillance, Epidemiology, and End Results program. JAMA Ophthalmol. 2014 Apr 1;132(4):478-83.[Abstract]

20. Global Retinoblastoma Study Group. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. Lancet Glob Health. 2022 Aug;10(8):e1128-40.[Abstract][Full Text]

21. Dimaras H, Kimani K, Dimba EA, et al. Retinoblastoma. Lancet. 2012 Apr 14;379(9824):1436-46.[Abstract][Full Text]

22. Mohammad M, Mehyar M, Halalsheh H, et al. The impact of tumor laterality (unilateral vs. bilateral) on presentation and management outcome in patients with retinoblastoma. J Clin Med. 2024 Apr 8;13(7):2146.[Abstract][Full Text]

23. Dimaras H, Khetan V, Halliday W, et al. Loss of RB1 induces non-proliferative retinoma; increasing genomic instability correlates with progression to retinoblastoma. Hum Mol Genet. 2008 May 15;17(10):1363-72.[Abstract]

24. Houston SK, Pina Y, Clarke J, et al. Regional and temporal differences in gene expression of LH(BETA)T(AG) retinoblastoma tumors. Invest Ophthalmol Vis Sci. 2011 Jul 23;52(8):5359-68.[Abstract][Full Text]

25. Leiderman YI, Kiss S, Mukai S. Molecular genetics of RB1 - the retinoblastoma gene. Semin Ophthalmol. 2007 Oct-Dec;22(4):247-54.[Abstract]

26. Orjuela M, Castaneda VP, Ridaura C, et al. Presence of human papilloma virus in tumor tissue from children with retinoblastoma: an alternative mechanism for tumor development. Clin Cancer Res. 2000 Oct;6(10):4010-6.[Abstract][Full Text]

27. Mohan A, Venkatesan N, Kandalam M, et al. Detection of human papillomavirus DNA in retinoblastoma samples: a preliminary study. J Pediatr Hematol Oncol. 2009 Jan;31(1):8-13.[Abstract]

28. Feng H, Deng Y. Human papillomavirus and retinoblastoma: evidence from a systematic review and meta-analysis of cross-sectional studies. Int J Public Health. 2023 Jul 11:68:1605284.[Abstract][Full Text]

29. Soltani S, Tabibzadeh A, Yousefi P, et al. HPV infections in retinoblastoma: a systematic review. J Clin Lab Anal. 2021 Oct;35(10):e23981.[Abstract][Full Text]

30. Dryja TP, Mukai S, Petersen R, et al. Parental origin of mutations of the retinoblastoma gene. Nature. 1989 Jun 15;339(6225):556-8.[Abstract]

31. DerKinderen DJ, Koten JW, Tan KE, et al. Parental age in sporadic hereditary retinoblastoma. Am J Ophthalmol. 1990 Dec 15;110(6):605-9.[Abstract]

32. Matsunaga E, Minoda K, Sasaki MS. Parental age and seasonal variation in the births of children with sporadic retinoblastoma: a mutation-epidemiologic study. Hum Genet. 1990 Jan;84(2):155-8.[Abstract]

33. Tanwar M, Balaji S, Vanniarajan A, et al. Parental age and retinoblastoma-a retrospective study of demographic data and genetic analysis. Eye (Lond). 2022 Jan;36(1):57-63.[Abstract][Full Text]

34. Saremi L, Imani S, Rostaminia M, et al. Parental age-related risk of retinoblastoma in Iranian children. Asian Pac J Cancer Prev. 2014;15(6):2847-50.[Abstract][Full Text]

35. Ajioka I, Dyer MA. A new model of tumor susceptibility following tumor suppressor gene activation. Cell Cycle. 2008 Mar 15;7(6):735-40.[Abstract]

36. Xu K, Rosenwaks Z, Beaverson K, et al. Preimplantation genetic diagnosis for retinoblastoma: the first reported liveborn. Am J Ophthalmol. 2004 Jan;137(1):18-23.[Abstract]

37. Skalet AH, Gombos DS, Gallie BL, et al. Screening children at risk for retinoblastoma: consensus report from the American Association of Ophthalmic Oncologists and Pathologists. Ophthalmology. 2018 Mar;125(3):453-8.[Abstract][Full Text]

38. Truong B, Green AL, Friedrich P, et al. Ethnic, racial, and socioeconomic disparities in retinoblastoma. JAMA Pediatr. 2015 Dec;169(12):1096-104.[Abstract]

39. American Academy of Ophthalmology. ​Review of retinoblastoma. Apr 2016 [internet publication].[Full Text]

40. Houston SK, Berrocal AM, Murray TG. The future of diagnostic imaging in retinoblastoma. J AAPOS. 2011 Apr;15(2):125-6.[Abstract]

41. de Graaf P, Goricke S, Rodjan F, et al. Guidelines for imaging retinoblastoma: imaging principles and MRI standardization. Pediatr Radiol. 2012 Jan;42(1):2-14.[Abstract][Full Text]

42. American College of Radiology. ACR appropriateness criteria: orbits, vision and visual loss. 2017 [internet publication].[Abstract][Full Text]

43. Rauschecker AM, Patel CV, Yeom KW, et al. High-resolution MR imaging of the orbit in patients with retinoblastoma. Radiographics. 2012 Sep-Oct;32(5):1307-26.[Abstract][Full Text]

44. Mohney BG, Robertson DM. Ancillary testing for metastasis in patients with newly diagnosed retinoblastoma. Am J Ophthalmol. 1994 Dec 15;118(6):707-11.[Abstract]

45. Stenfelt S, Blixt MKE, All-Ericsson C, et al. Heterogeneity in retinoblastoma: a tale of molecules and models. Clin Transl Med. 2017 Nov 9;6(1):42.[Abstract][Full Text]

46. Rodriguez-Galindo C, Orbach DB, VanderVeen D. Retinoblastoma. Pediatr Clin North Am. 2015 Feb;62(1):201-23.[Abstract]

47. Berry JL, Pike S, Shah R, et al. Aqueous humor liquid biopsy as a companion diagnostic for retinoblastoma: implications for diagnosis, prognosis, and therapeutic options: five years of progress. Am J Ophthalmol. 2024 Jul;263:188-205.[Abstract][Full Text]

48. Ghose N, Kaliki S. Liquid biopsy in retinoblastoma: a review. Semin Ophthalmol. 2022 Oct-Nov;37(7-8):813-9.[Abstract][Full Text]

49. Silva RA, Dubovy SR, Fernandes CE, et al. Retinoblastoma with Coats' response. Ophthalmic Surg Lasers Imaging. 2011 Dec 16;42 Online:e139-43.[Abstract]

50. Hutchinson AK, Morse CL, Hercinovic A, et al. Pediatric eye evaluations preferred practice pattern. Ophthalmology. 2023 Mar;130(3):P222-70.[Abstract][Full Text]

51. Gerrish A, Bowns B, Mashayamombe-Wolfgarten C, et al. Non-invasive prenatal diagnosis of retinoblastoma inheritance by combined targeted sequencing strategies. J Clin Med. 2020 Oct 30;9(11):3517.[Abstract][Full Text]

52. American Academy of Ophthalmology. Retinoblastoma. Feb 2024 [internet publication].​[Full Text]

53. Meel R, Kulkarni S, Singh L, et al. Management of intraocular retinoblastoma: ICMR consensus guidelines. Indian J Pediatr. 2024 Apr 13.[Abstract]

54. Royal College of Pathologists. Standards and datasets for reporting cancers. Dataset for histopathological reporting of ocular retinoblastoma. January 2018 [internet publication].[Full Text]

55. Chantada GL, Doz F, Orjuela M, et al. World disparities in risk definition and management of retinoblastoma: a report from the International Retinoblastoma Staging Working Group. Pediatr Blood Cancer. 2008 Mar;50(3):692-4.[Abstract]

56. Howarth C, Meyer D, Hustu HO, et al. Stage-related combined modality treatment of retinoblastoma. Results of a prospective study. Cancer. 1980 Mar 1;45(5):851-8.[Abstract]

57. Abramson DH, Ellsworth RM. The surgical management of retinoblastoma. Ophthalmic Surg. 1980 Sep;11(9):596-8.[Abstract]

58. Schefler AC, Cicciarelli N, Feuer W, et al. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology. 2007 Jan;114(1):162-9.[Abstract]

59. Gobin YP, Dunkel IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011 Jun;129(6):732-7.[Abstract]

60. Lumbroso-Le Rouic L, Blanc R, Saint Martin C, et al. Selective ophthalmic artery chemotherapy with melphalan in the management of unilateral retinoblastoma: a prospective study. Ophthalmol Retina. 2021 Aug;5(8):e30-7.[Abstract]

61. Francis JH, Roosipu N, Levin AM, et al. Current treatment of bilateral retinoblastoma: the impact of intraarterial and intravitreous chemotherapy. Neoplasia. 2018 Aug;20(8):757-63.[Abstract][Full Text]

62. Abramson DH, Daniels AB, Marr BP, et al. Intra-arterial chemotherapy (ophthalmic artery chemosurgery) for group D retinoblastoma. PLoS One. 2016 Jan 12;11(1):e0146582.[Abstract][Full Text]

63. Chen Q, Zhang B, Dong Y, et al. Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis. BMC Cancer. 2018 Apr 27;18(1):486.[Abstract][Full Text]

64. Wen X, Fan J, Jin M, et al. Intravenous versus super-selected intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial. Lancet Child Adolesc Health. 2023 Sep;7(9):613-20.[Abstract]

65. Cao Y, Zhou M, Tian M, et al. The safety and effectiveness of melphalan-based intra-arterial chemotherapy for retinoblastoma: an updated single-arm systematic review and meta-analysis. Evid Based Complement Alternat Med. 2022 Feb 14:2022:3156503.[Abstract][Full Text]

66. Ghassemi F, Shields CL. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 2012 Oct;130(10):1268-71.[Abstract][Full Text]

67. Francis JH, Brodie SE, Marr B, et al. Efficacy and toxicity of intravitreous chemotherapy for retinoblastoma: four-year experience. Ophthalmology. 2017 Apr;124(4):488-95.[Abstract]

68. Francis JH, Iyer S, Gobin YP, et al. Retinoblastoma vitreous seed clouds (class 3): a comparison of treatment with ophthalmic artery chemosurgery with or without intravitreous and periocular chemotherapy. Ophthalmology. 2017 Oct;124(10):1548-55.[Abstract]

69. Munier FL, Gaillard MC, Balmer A, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol. 2012 Aug;96(8):1078-83.[Abstract]

70. Smith SJ, Smith BD. Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2013 Oct;97(10):1231-6.[Abstract]

71. Shields CL, Douglass AM, Beggache M, et al. Intravitreous chemotherapy for active vitreous seeding from retinoblastoma: outcomes after 192 consecutive injections - the 2015 Howard Naquin lecture. Retina. 2016 Jun;36(6):1184-90.[Abstract]

72. Ministry of Health and Family Welfare India. Retinoblastoma: standard treatment guidelines. 2016 [internet publication].[Full Text]

73. Houston SK, Wykoff CC, Berrocal AM, et al. Lasers for the treatment of intraocular tumors. Lasers Med Sci. 2013 May;28(3):1025-34.[Abstract]

74. Manjandavida FP, Honavar SG, Reddy VA, et al. Management and outcome of retinoblastoma with vitreous seeds. Ophthalmology. 2014 Feb;121(2):517-24.[Abstract]

75. Gündüz AK, Mirzayev I, Temel E, et al. A 20-year audit of retinoblastoma treatment outcomes. Eye (Lond). 2020 Oct;34(10):1916-24.[Abstract][Full Text]

76. Tomar AS, Finger PT, Gallie B, et al. Retinoblastoma seeds: impact on American Joint Committee on Cancer clinical staging. Br J Ophthalmol. 2023 Jan;107(1):127-32.[Abstract][Full Text]

77. Leng T, Cebulla CM, Schefler AC, et al. Focal periocular carboplatin chemotherapy avoids systemic chemotherapy for unilateral, progressive retinoblastoma. Retina. 2010;30(suppl 4):S66-8.[Abstract]

78. Mulvihill A, Budning A, Jay V, et al. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol. 2003 Aug;121(8):1120-4.[Abstract]

79. Schmack I, Hubbard GB, Kang SJ, et al. Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for retinoblastoma. Am J Ophthalmol. 2006 Aug;142(2):310-5.[Abstract]

80. Uusitalo MS, Van Quill KR, Scott IU, et al. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol. 2001 Jan;119(1):41-8.[Abstract]

81. Chantada GL, Dunkel IJ, de Dávila MT, et al. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol. 2004 Aug;88(8):1069-73.[Abstract][Full Text]

82. Zelter M, Damel A, Gonzalez G, et al. A prospective study on the treatment of retinoblastoma in 72 patients. Cancer. 1991 Oct 15;68(8):1685-90.[Abstract]

83. Kiratli H, Bilgiç S, Ozerdem U. Management of massive orbital involvement of intraocular retinoblastoma. Ophthalmology. 1998 Feb;105(2):322-6.[Abstract]

84. Goble RR, McKenzie J, Kingston JE, et al. Orbital recurrence of retinoblastoma successfully treated by combined therapy. Br J Ophthalmol. 1990 Feb;74(2):97-8.[Abstract][Full Text]

85. Doz F, Khelfaoui F, Mosseri V, et al. The role of chemotherapy in orbital involvement of retinoblastoma: the experience of a single institution with 33 patients. Cancer. 1994 Jul 15;74(2):722-32.[Abstract]

86. Sandri A, Besenzon L, Acquaviva A, et al. "Eight drugs in one day" chemotherapy in a nonfamilial bilateral retinoblastoma with recurrent cerebrospinal fluid metastases. Pediatr Hematol Oncol. 1998 Nov-Dec;15(6):557-61.[Abstract]

87. Doz F, Neuenschwander S, Plantaz D, et al. Etoposide and carboplatin in extraocular retinoblastoma: a study by the Société Française d'Oncologie Pédiatrique. J Clin Oncol. 1995 Apr;13(4):902-9.[Abstract]

88. Namouni F, Doz F, Tanguy ML, et al. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study. Eur J Cancer. 1997 Dec;33(14):2368-75.[Abstract]

89. White L. Chemotherapy for retinoblastoma. Med Pediatr Oncol. 1995 May;24(5):341-2.[Abstract]

90. Schouten-Van Meeteren AY, Moll AC, Imhof SM, et al. Overview: chemotherapy for retinoblastoma: an expanding area of clinical research. Med Pediatr Oncol. 2002 Jun;38(6):428-38.[Abstract]

91. Matsubara H, Makimoto A, Higa T, et al. A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant. 2005 Apr;35(8):763-6.[Abstract]

92. Kremens B, Wieland R, Reinhard H, et al. High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma. Bone Marrow Transplant. 2003 Feb;31(4):281-4.[Abstract]

93. Hertzberg H, Kremens B, Velten I, et al. Recurrent disseminated retinoblastoma in a 7-year-old girl treated successfully by high-dose chemotherapy and CD34-selected autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2001 Mar;27(6):653-5.[Abstract]

94. Dunkel IJ, Aledo A, Kernan NA, et al. Successful treatment of metastatic retinoblastoma. Cancer. 2000 Nov 15;89(10):2117-21.[Abstract]

95. Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for retinoblastoma: long-term tumor control and treatment complications in 208 tumors. Ophthalmology. 2001 Nov;108(11):2116-21.[Abstract]

96. Merchant TE, Gould CJ, Wilson MW, et al. Episcleral plaque brachytherapy for retinoblastoma. Pediatr Blood Cancer. 2004 Aug;43(2):134-9.[Abstract]

97. Scott IU, Murray TG, Feuer WJ, et al. External beam radiotherapy in retinoblastoma: tumor control and comparison of 2 techniques. Arch Ophthalmol. 1999 Jun;117(6):766-70.[Abstract]

98. Abramson DH, Beaverson KL, Chang ST, et al. Outcome following initial external beam radiotherapy in patients with Reese-Ellsworth group Vb retinoblastoma. Arch Ophthalmol. 2004 Sep;122(9):1316-23.[Abstract]

99. Canadian Ophthalmological Society (Canadian Retinoblastoma Society). National retinoblastoma strategy: Canadian guidelines for care (Stratégie thérapeutique du rétinoblastome guide clinique canadien). Can J Ophthalmol. 2009;44(Suppl 2):S1-S88.[Abstract][Full Text]

100. Silva RA, Dubovy SR, Hess D, et al. Hemorrhage as a sign of treatment failure after intra-arterial chemotherapy in retinoblastoma. J AAPOS. 2015 Jun;19(3):268-70.[Abstract]

101. Rivera GK, Pui CH, Santana VM, et al. Epipodophyllotoxins in the treatment of childhood cancer. Cancer Chemother Pharmacol. 1994;34 Suppl:S89-S95.[Abstract]

102. Azary S, Ganguly A, Bunin GR, et al. Sporadic Retinoblastoma and Parental Smoking and Alcohol Consumption before and after Conception: A Report from the Children's Oncology Group. PLoS One. 2016;11(3):e0151728.[Abstract][Full Text]